#USA #New Orleans #MolecuLight #VAM 2025 #Wound Imaging

MolecuLight to Showcase Innovative Wound Imaging Platform at VAS 2025

MolecuLight Inc., a prominent player in fluorescence imaging technology for rapid bacterial detection, is excited to announce its attendance at the Vascular Annual Meeting (VAM) 2025, hosted by the Society for Vascular Surgery (SVS) in New Orleans, Louisiana, from June 4 to 7, 2025.

At booth 654, the company will introduce its cutting-edge device, DX™, which provides real-time insights into wound characteristics. This includes detecting bacterial presence, offering digital measurements of wounds, and incorporating thermography to visualize temperature changes. These features contribute significantly to enhancing wound care, providing essential data for informed clinical decisions.

The SVS VAM is a paramount global event tailored for vascular surgeons and health professionals dedicated to advancing vascular health. MolecuLight’s offerings coincide with this mission by supplying objective, evidence-based data that empower healthcare professionals to better assess and address patient needs in real time.

Moreover, MolecuLight is proud to announce that Dr. Alisha Oropallo has been awarded the Outstanding Presentation Award by the Society for Vascular Surgery’s Ambulatory Vascular Care Section (SAVC) for her abstract titled, "An Objective Comparative Study of Non-Surgical Cleansing Techniques and Types of Cleansers in the Treatment of Bacterial Load." Dr. Oropallo will present her awarded research during the VAM SAVC session on June 6. This study underscores the critical necessity for objective assessments in wound management and aligns seamlessly with MolecuLight's commitment to providing healthcare providers with the tools necessary for effective bacterial load treatment.

"We are thrilled to be participating in the SVS Vascular Annual Meeting and to connect with leading vascular surgeons," said Anil Amlani, CEO of MolecuLight. "We congratulate Dr. Oropallo on this well-deserved recognition, and we are proud that her research, which highlights the need for crucial objective data in wound care, is presented at this prestigious meeting."

Attendees of the SVS Vascular Annual Meeting are warmly invited to visit MolecuLight at booth 654 to gather more information about the DX device and discover how MolecuLight's innovative wound imaging platform can enhance clinical efficiency.

About the SVS Vascular Annual Meeting

The SVS Vascular Annual Meeting is the leading international forum for vascular surgeons and other health professionals focused on vascular disease science, diagnosis, and treatment. This annual event gathers industry experts from around the globe to share the latest research, advancements, and best practices in vascular care. It offers a comprehensive educational experience through scientific sessions, interactive workshops, and network opportunities, all designed to enhance patient outcomes and promote advancements in vascular surgery.

About MolecuLight Inc.

MolecuLight Inc. is a privately held global medical imaging company that manufactures and markets the MolecuLight iX® and DX™ wound imaging devices. These are the only FDA-cleared Class II point-of-care imaging devices capable of real-time detection of elevated bacterial load in wounds. Additionally, they provide accurate digital measurements of wounds for comprehensive treatment, supported by a robust body of clinical evidence, including over 100 peer-reviewed publications. For sales, press inquiries, or more information, please contact Danielle Dunham, Product Director, MolecuLight Inc., at +1.416.542.5524 or email protected] [www.MolecuLight.com.